A “practice-changing” immunotherapy drug combination demonstrated inhibition of two main immune checkpoints in a trial assessing efficacy in metastatic melanoma.
List view / Grid view
Jessicca Rege of Alkermes provides insights into how protein engineering approaches have led to the development of novel therapies that harness the immune system’s capabilities to fight cancer.
The FDA has granted fast track designation for Evaxion’s personalised cancer vaccine in combination Keytruda® for patients with metastatic melanoma.
The scale up in annual capacity and expansion of Achilles' global clinical manufacturing footprint will see its second site in the UK and first site to be established in the US.
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
A study has reported that almost 40 percent of patients with non-surgically treatable tumours were effectively treated using a genetically modified virus...
Scientists have tried combining drugs in an effort to prevent resistance development that eventually leads to cancer regrowth in melanoma patients.